Sartorius, a leading international partner of life science research and the biopharmaceutical industry, has supported CanSino Biologics Inc. (\u201cCanSinoBIO\u201d) and Maj. Gen. Chen Wei\u2019s team at the Institute of Bioengineering at the Academy of Military Medical Sciences (\u201cInstitute of Bioengineering\u201d) in China in their development of the first vaccine candidate against the novel coronavirus SARS-CoV-2 to enter clinical trials. CanSinoBIO and the Institute of Bioengineering used Sartorius\u2019 BIOSTAT\u00ae STR single-use bioreactor system for the upstream preparation of the recombinant vaccine, thus ensuring the rapid linear amplification of the adenovirus vector (Ad5-nCoV) and ultimately saving time during development.
\nThe BIOSTAT\u00ae STR single-use bioreactor system comes with updated BioPAT\u00ae toolbox for process monitoring, as well as Flexsafe\u00ae STR integrated, single-use bioprocess bags. It has been proven to be used for vaccine manufacturing because it offers rapid scalability and flexibility to adapt to fluctuating demand. The single use bags prevent cross-contamination, and reduce the time needed for washing and sanitation typical in stainless steel bioreactors. As such, the amount of time needed to prepare a vector for a vaccine is shortened from several months to (several) weeks.
\n\u201cWe are pleased that we can help our clients and partners accelerate vaccine development while maintaining compliance with safety protocols, thereby allowing us to contribute to better health for more people,\u201d said Huang Xian, Head of Marketing at Sartorius BPS China.
\nThis is the second collaboration from Sartorius, CanSinoBIO, and the Institute of Bioengineering to accelerate vaccine development. In October 2017, Sartorius\u2019 BIOSTAT\u00ae STR50 bioreactor system was used during CanSinoBIO\u2019s and the Institute of Bioengineering\u2019s joint development of a recombinant vaccine against Ebola virus disease. This was the first registered Ebola vaccine in the world.<\/p>\n","protected":false},"excerpt":{"rendered":"
Sartorius, a leading international partner of life science research and the biopharmaceutical industry, has supported CanSino Biologics Inc. (\u201cCanSinoBIO\u201d) and Maj. Gen. Chen Wei\u2019s team at the Institute of Bioengineering at the Academy of Military Medical Sciences (\u201cInstitute of Bioengineering\u201d) in China in their development of the first vaccine candidate against the novel coronavirus SARS-CoV-2 […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[35],"tags":[],"_links":{"self":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/689"}],"collection":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/comments?post=689"}],"version-history":[{"count":0,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/689\/revisions"}],"wp:attachment":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media?parent=689"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/categories?post=689"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/tags?post=689"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}